Navigating Shareholder Litigation Risk in the Life Sciences Sector
Risk & Insurance - Mar 02, 2026
From clinical trial readouts to regulatory uncertainty, life science companies face unique D&O exposures at every stage of development — but disciplined practices and specialized insurance support can help mitigate the risk. The post Navigating Shareholder Litigation Risk in the Life Sciences S...
Recommended Articles
Posted: Apr 16, 2026
A joint report from the Insurance Information Institute and Fenix24 found that insurers, despite set...
Posted: Apr 16, 2026
Jeff Green, the risk manager for Larimer County, Colo. Recounts his years in the profession and why...
Posted: Apr 15, 2026
Poor communication contributes to nearly 70% of workplace incidents, underscoring the business case...